BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 2804925)

  • 1. Refractory anemia with excess of blasts in transformation hematologic and clinical study of 52 patients.
    Michels SD; Saumur J; Arthur DC; Robison LL; Brunning RD
    Cancer; 1989 Dec; 64(11):2340-6. PubMed ID: 2804925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High remission rate, short remission duration in patients with refractory anemia with excess blasts (RAEB) in transformation (RAEB-t) given acute myelogenous leukemia (AML)-type chemotherapy in combination with granulocyte-CSF (G-CSF).
    Estey EH; Kantarjian HM; O'Brien S; Kornblau S; Andreeff M; Beran M; Pierce S; Keating M
    Cytokines Mol Ther; 1995 Mar; 1(1):21-8. PubMed ID: 9384660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of intensive AML-specific therapy in treatment of children with RAEB and RAEB-t.
    Creutzig U; Bender-Götze C; Ritter J; Zimmermann M; Stollmann-Gibbels B; Körholz D; Niemeyer C
    Leukemia; 1998 May; 12(5):652-9. PubMed ID: 9593261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of clonal chromosomal abnormalities in patients with primary myelodysplastic syndromes.
    Gyger M; Infante-Rivard C; D'Angelo G; Forest L; Lussier P
    Am J Hematol; 1988 May; 28(1):13-20. PubMed ID: 3369432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Refractory cytopenia with multilineage dysplasia: further characterization of an 'unclassifiable' myelodysplastic syndrome.
    Rosati S; Mick R; Xu F; Stonys E; Le Beau MM; Larson R; Vardiman JW
    Leukemia; 1996 Jan; 10(1):20-6. PubMed ID: 8558932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Refractory anemia with excess of blasts in transformation: analysis of reclassification according to the WHO proposals.
    Strupp C; Gattermann N; Giagounidis A; Aul C; Hildebrandt B; Haas R; Germing U
    Leuk Res; 2003 May; 27(5):397-404. PubMed ID: 12620291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy.
    Fenaux P; Morel P; Rose C; Lai JL; Jouet JP; Bauters F
    Br J Haematol; 1991 Apr; 77(4):497-501. PubMed ID: 2025575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy.
    Estey E; Thall P; Beran M; Kantarjian H; Pierce S; Keating M
    Blood; 1997 Oct; 90(8):2969-77. PubMed ID: 9376577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic significance of auer rods in myelodysplasia.
    Seymour JF; Estey EH
    Br J Haematol; 1993 Sep; 85(1):67-76. PubMed ID: 8251411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of chromosome 22 in patients with refractory anemia with excess of blasts (RAEB) in transformation and acute leukemia after RAEB.
    Berger R; Le Coniat M; Derré J; Flexor MA
    Cancer Genet Cytogenet; 1992 Jul; 61(2):210-2. PubMed ID: 1638507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. De novo acute myeloid leukemia with 20-29% blasts is less aggressive than acute myeloid leukemia with ≥30% blasts in older adults: a Bone Marrow Pathology Group study.
    Hasserjian RP; Campigotto F; Klepeis V; Fu B; Wang SA; Bueso-Ramos C; Cascio MJ; Rogers HJ; Hsi ED; Soderquist C; Bagg A; Yan J; Ochs R; Orazi A; Moore F; Mahmoud A; George TI; Foucar K; Odem J; Booth C; Morice W; DeAngelo DJ; Steensma D; Stone RM; Neuberg D; Arber DA
    Am J Hematol; 2014 Nov; 89(11):E193-9. PubMed ID: 25042343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Refractory anemia with excess of blasts in transformation. Clinical, hematologic, and cytogenetic findings in nine patients.
    Smadja N; Krulik M; de Gramont A; Gonzalez-Canali G; Audebert AA; Debray J
    Cancer Genet Cytogenet; 1989 Oct; 42(1):55-65. PubMed ID: 2790747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome of children with refractory anaemia with excess of blast (RAEB) and RAEB in transformation (RAEB-T) in the Japanese MDS99 study.
    Kikuchi A; Hasegawa D; Ohtsuka Y; Hamamoto K; Kojima S; Okamura J; Nakahata T; Manabe A;
    Br J Haematol; 2012 Sep; 158(5):657-61. PubMed ID: 22734597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Refractory anaemia with excess of blasts (RAEB): analysis of reclassification according to the WHO proposals.
    Germing U; Strupp C; Kuendgen A; Aivado M; Giagounidis A; Hildebrandt B; Aul C; Haas R; Gattermann N
    Br J Haematol; 2006 Jan; 132(2):162-7. PubMed ID: 16398650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of time to complete remission on subsequent survival and disease-free survival time in AML, RAEB-t, and RAEB.
    Estey EH; Shen Y; Thall PF
    Blood; 2000 Jan; 95(1):72-7. PubMed ID: 10607687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Re-evaluation of refractory anemia with excess blasts in transformation.
    Ohyashiki K; Nishimaki J; Shoji N; Miyazawa K; Kimura Y; Ohyashiki JH
    Leuk Res; 2001 Nov; 25(11):933-9. PubMed ID: 11597728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myelodysplastic syndromes. A clinical and pathologic analysis of 109 cases.
    Foucar K; Langdon RM; Armitage JO; Olson DB; Carroll TJ
    Cancer; 1985 Aug; 56(3):553-61. PubMed ID: 3891071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with AML, secondary AML, and refractory anemia with excess blasts in transformation.
    Saito K; Nakamura Y; Aoyagi M; Waga K; Yamamoto K; Aoyagi A; Inoue F; Nakamura Y; Arai Y; Tadokoro J; Handa T; Tsurumi S; Arai H; Kawagoe Y; Gunnji H; Kitsukawa Y; Takahashi W; Furusawa S
    Int J Hematol; 2000 Apr; 71(3):238-44. PubMed ID: 10846828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
    Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
    Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complex chromosomal abnormalities in a patient with refractory anemia with excess blasts (RAEB).
    Christodoulidou F; Coleman M; Macera MJ; Verma RS
    Cancer Genet Cytogenet; 1991 Jul; 54(2):229-32. PubMed ID: 1884355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.